Advancing Innovation in Dermatology - Blog

Build in Derm: From Signal to Story

Written by Vijendra Nalamothu, PhD | Nov 20, 2026, 12:00:00 PM

Build in Derm distills practical guidance from AID's Entrepreneur Bootcamp for researchers and founders working to move dermatology innovation forward.

Compelling science does not automatically translate into an investable development program. At the 2026 Dermatology Innovation Forum Entrepreneur Bootcamp, Vijendra Nalamothu, PhD, Founder and CEO of ApoStrata, shared a practical framework for moving from a promising signal in skin to a developable product and investable company: evidence before elegance, and de-risking before scale.


Make the Story Hold Together

For an early topical dermatology program, the preclinical signal, formulation logic, intellectual property, regulatory route, and commercial direction must point toward the same (drug) product. That requires founders to continually reassess the lead indication, early data, evolving target product profile, IP position, and regulatory strategy as the program develops.

Choose Studies That Change the Financing Discussion

Founders naturally gravitate toward scientifically interesting questions. Investors, however, need evidence that changes a development or financing decision. A useful next study is not simply one that adds data; it is one that addresses the key uncertainty limiting progress – whether in biology, delivery, safety, manufacturability or an unmet need.

For topical dermatology, early evidence should establish four things:

  1. The biology works in skin – not just in a broad in vitro screen.
  2. The dosage form delivers drug where the target biology sits.
  3. Local and systemic safety appear manageable.
  4. The formulation behaves reproducibly enough to become a product.

Together, these form a financeable data package: evidence that resolves a development risk rather than simply adding more science.

Build IP and Regulatory Strategy Alongside the Science

One upstream question shapes much of the strategy: is the asset a new chemical entity or a known molecule? The answer affects manufacturing, supply, regulatory planning, and how the company can build a defensible IP position. For known molecules, value may depend on formulation, method-of-use, process, or other claims, and freedom to operate must be revisited as the program evolves.

Regulatory strategy should develop alongside the science. The product classification and pathway will shape the evidence required, development timeline, and cost. Early FDA engagement can clarify what matters most, particularly when ex-U.S. studies may support a U.S. program. Strong IP and a credible regulatory strategy do more than reduce risk; they create optionality for fundraising and partnering.

Know When Exploration Becomes Execution

Nalamothu recommends advancing when the next dollar buys execution rather than open-ended exploration. Five signals can indicate that an idea is ready to move into development:

  1. Signal in skin: Repeatable activity at a realistic dose in a relevant model.
  2. Formulation behaves: Release, permeation, stability, and manufacturability support a real dosage form.
  3. Moat is defendable: Potential claims are visible and key FTO risks are understood.
  4. FDA route is credible: The team can explain the likely pathway and why it fits.
  5. Market wedge is real: The lead indication and prescriber segment are focused enough to win.

The founder rule is practical: when the next critical work looks like formulation, intellectual property, regulatory strategy, and launch preparation - not simply more discovery - the idea is beginning to enter development.

Give Differentiation a Commercial Context

Differentiation alone is not a commercial strategy. Founders should benchmark the product against current and emerging competitors, keep the TPP responsive to new evidence, and begin testing assumptions about cost, access, prescriber concentration, and the first indication the company can realistically win.

Raise Capital for a Proof Point

A capital raise should fund a defined value inflection, not general exploration. The use of proceeds should connect directly to milestones such as formulation lock, translational proof, a stronger IP position, or a clearer regulatory route. Work that reduces a specific risk and improves valuation or partnering leverage.

Investors do not need certainty, but they do need to see a visible sequence of de-risking events that can improve the next financing or partnering decision.

Get Focused Input Through DLC Office Hours

AID's Development Leadership Council offers structured, 20-minute, pro-bono consultations for early-stage dermatology companies. Applicants submit a brief, non-confidential deck and up to three focused questions in advance.

Whether your open question involves intellectual property, translational validity, biomarker strategy, or the next 12 to 24 months, Office Hours can provide focused feedback from experienced dermatology operators and development leaders.

Ready to check out our Development Leadership Council and their resources?
Learn more about the DLC Office Hours.